ORPHA:280333
Alpha-dystroglycan-related limb-girdle muscular dystrophy R16
Also known as: Alpha-dystroglycan-related LGMD R16 · Autosomal recessive limb-girdle muscular dystrophy type 2P · LGMD type 2P · LGMD2P · Limb-girdle muscular dystrophy type 2P
Query health: suspect — Only one of 2 strategies returned hits (phrase).
Publications
25
33.9th percentile
Trials
0
Interventional, condition-specific
Researchers
191
Distinct authors in sample
Gene link
DAG1
Definitive
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
A form of limb-girdle muscular characterized by slowly-, mainly proximal, muscle weakness presenting in early childhood (with difficulties walking and climbing stairs) and mild to severe . Additional manifestations reported include microcephaly, mild increase in thigh or calf muscles, and contractures of the ankles.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0013440
- OMIM:613818
- UMLS:C4511963
Additional Mondo synonyms (3)
DAG1 autosomal recessive limb-girdle muscular dystrophy · MDDGC9 · autosomal recessive limb-girdle muscular dystrophy caused by mutation in DAG1
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedPresent
Definitive — DAG1
- LiteraturePresent
25 matched papers (16 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPartial
None under the specific name; 24 for broader category limb-girdle muscular dystrophy
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (DAG1).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
25
25 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
25 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
16 in the last 10 years · high confidence · 33.9th percentile (publications denominator)
Phrase hits: 25 · MeSH hits: 0
Who's working on it?
191
Distinct author names in 25 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Brancaccio A4 papers · 2025
School of Biochemistry, University of Bristol, Bristol, BS8 1TD, United Kingdom; Istituto di Chimica del Riconoscimento Molecolare-CNR, c/o Università Cattolica del Sacro Cuore, Roma, 00168, Italy.
Papers in Europe PMC - 02Bigotti MG2 papers · 2025
School of Biochemistry, University of Bristol, Bristol, BS8 1TD, United Kingdom.
Papers in Europe PMC - 03Bozzi M2 papers · 2025
Istituto di Biochimica e Biochimica Clinica, Università Cattolica del Sacro Cuore, Roma 00168, Italy.
Papers in Europe PMC - 04Campbell KP2 papers · 2025
Howard Hughes Medical Institute, The University of Iowa, Iowa City, IA 52242; Department of Molecular Physiology and Biophysics, The University of Iowa, Iowa City, IA 52242; Department of Neurology, The University of Iowa, Iowa City, IA 52242; Department of Internal Medicine, The University of Iowa, Iowa City, IA 52242; kevin-campbell@uiowa.edu.
Papers in Europe PMC - 05Cassetta A2 papers · 2025
Istituto di Cristallografia-CNR, Trieste Outstation, Trieste, 34149, Italy.
Papers in Europe PMC - 06Covaceuszach S2 papers · 2025
Istituto di Cristallografia-CNR, Trieste Outstation, Trieste, 34149, Italy.
Papers in Europe PMC - 07Hübner W2 papers · 2025
Department of Physics, University of Bielefeld, 33615, Bielefeld, Germany.
Papers in Europe PMC - 08Sciandra F2 papers · 2025
Istituto di Chimica del Riconoscimento Molecolare-CNR, c/o Università Cattolica del Sacro Cuore, Roma, 00168, Italy.
Papers in Europe PMC - 09Acosta SA1 paper · 2023
School of Life Sciences, Arizona State University, Tempe, AZ 85287-4501, USA.
Papers in Europe PMC - 10Akaaboune M1 paper · 2025
Department of Molecular, Cellular, and Developmental Biology, Ann Arbor, MI, United States.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name. 2 observational studies did — shown below because natural-history and cohort work can be an important step toward a trial. 24 trials are registered for limb-girdle muscular dystrophy, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
high confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
24 interventional trials matched limb-girdle muscular dystrophy, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: limb-girdle muscular dystrophy
24
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07711730·RECRUITING·Telecare Psychosocial and Cognitive Intervention for Children and Adolescents With Limb-Girdle Muscular Dystrophy
Conditions: Limb-Girdle Muscular Dystrophy · Social Competence · Self Esteem · Health Related Quality of Life·Matched via name phrase
- NCT05230459·RECRUITING·A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)
Conditions: Limb Girdle Muscular Dystrophy · Limb-Girdle Muscular Dystrophy Type 2 · LGMD2I · Muscular Dystrophy·Matched via name phrase
Observational and natural-history studies
2 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT05989620·RECRUITING·Long-Term Development of Muscular Dystrophy Outcome Assessments
Conditions: LGMD1B · LGMD1C · LGMD1D · LGMD1E·Matched via name phrase
- NCT01403402·RECRUITING·Congenital Muscle Disease Study of Patient and Family Reported Medical Information
Conditions: Congenital Muscular Dystrophy With ITGA7 (Integrin Alpha-7) Deficiency · Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy and Abnormal Glycosylation of Dystroglycan With Severe Epilepsy) · Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy With Fatty Liver and Infantile-onset Cataract Caused by TRAPPC11 Mutations) · Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy With Hypoglycosylation of Dystroglycan)·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Alpha-dystroglycan-related limb-girdle muscular dystrophy R16" OR "Alpha-dystroglycan-related LGMD R16" OR "Autosomal recessive limb-girdle muscular dystrophy type 2P" OR "LGMD type 2P" OR "LGMD2P" OR "Limb-girdle muscular dystrophy type 2P" OR "DAG1 autosomal recessive limb-girdle muscular dystrophy" OR "MDDGC9" OR "autosomal recessive limb-girdle muscular dystrophy caused by mutation in DAG1"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Alpha-dystroglycan-related limb-girdle muscular dystrophy R16" OR "Alpha-dystroglycan-related LGMD R16" OR "Autosomal recessive limb-girdle muscular dystrophy type 2P" OR "LGMD type 2P" OR "LGMD2P" OR "Limb-girdle muscular dystrophy type 2P" OR "DAG1 autosomal recessive limb-girdle muscular dystrophy" OR "MDDGC9" OR "autosomal recessive limb-girdle muscular dystrophy caused by mutation in DAG1" OR "DAG1" OR "muscular dystrophy-dystroglycanopathy, type C" OR "autosomal recessive limb-girdle muscular dystrophy" OR "muscular dystrophy-dystroglycanopathy"
Recall-expansion terms: DAG1, muscular dystrophy-dystroglycanopathy, type C, autosomal recessive limb-girdle muscular dystrophy, muscular dystrophy-dystroglycanopathy
Study-type breakdown: 0 interventional · 2 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"limb-girdle muscular dystrophy"
Query health: suspect — strategies attempted: phrase, recall-expansion; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T11:53:10.290Z